Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 8/20 | 0.53 |
| ▸ | CCND1 | P24385 | 8/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.53 |
| ▸ | CDK2 | P24941 | 4/20 | 0.53 |
| ▸ | HTR1A | P08908 | 11/20 | 0.45 |
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | DRD3 | P35462 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7000600 | 0.87 | HTR1A (0.45) | CDK4CCND1CCNE2CCNE1CDK2 | |
| Hydrochloric Acid SCHEMBL7002842 | 0.86 | HTR1A (0.49) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7005934 | 0.84 | HTR1A (0.42) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7004655 | 0.84 | HTR1A (0.48) | CDK4CCND1HTR1ADRD2DRD3 | |
| SCHEMBL7008105 | 0.82 | MTNR1A (0.50) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7002574 | 0.80 | CTSL (0.44) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7004925 | 0.79 | CTSL (0.40) | CDK4CCND1CCNE2CCNE1CDK2 | |
| Hydrochloric Acid SCHEMBL7004253 | 0.79 | HTR1A (0.42) | CDK4CCND1CCNE2CCNE1CDK2 | |
| Hydrochloric Acid SCHEMBL7001069 | 0.78 | HTR1A (0.71) | HTR1ADRD2DRD3 | |
| SCHEMBL7005958 | 0.78 | HTR1A (0.45) | CDK4CCND1CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105118-A1 | Tricyclic quinazolinediones | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1288216-A1 | TRICYCLIC QUINAZOLINEDIONES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105118-A1 | Tricyclic quinazolinediones | PARP1, PARP11, PARP2 | CDK4 754/4885CCND1 622/4885CCNE2 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.